STUDY OF INHIBITION OF B16F10 MELANOMA GROWTH IN MICE BY LANDOMYCIN A IN COMPARISON TO DOXORUBICIN
DOI: http://dx.doi.org/10.30970/sbi.1001.467
Abstract
Landomycin A is a new antibiotic of angucycline group with antineoplastic activity against tumor cells of different origin. In this work, we investigated the effects of landomycin A on the growth of B16F10 mouse melanoma. It was elucidated that studied antibiotic possessed a significant dose-dependent cytotoxic activity against these melanoma cells in vitro, and its LC50 = 2 µM was 5 times lower than that of the doxorubicin, anticancer drug widely used for treatment of solid tumors. Landomycin A at concentration of 10 mg/kg body weight did not cause pathological changes, mortality or general toxic symptoms in intact mice of C57black/6 line. No significant changes in the body weight and hematological parameters of animals treated with landomycin A as compared to the control group were observed. While B16F10 melanoma maintained rapid growth in vivo with a continual increase in tumor volume, landomycin A effectively inhibited tumor growth without a marked myelosuppressive effects or cardio- and hepatotoxicity that are characteristic for doxorubicin action. These results suggest a perspective of landomycin A application in chemotherapy of malignant tumors.
Keywords
Full Text:
PDFReferences
1. Adams R. Laboratory techniques in biochemistry and molecular biology. Elsevier, 1990. 16-94 p. | |
| |
2. Atallah E., Flaherty L. Treatment of metastatic malignant melanoma. Curr. Treat. Options Oncol, 2005; 6(3): 185-193. | |
| |
3. Botros M., Kenneth S. The De Ritis Ratio: The Test of Time. Clin. Biochem. Rev, 2013; 34: 117-130. | |
| |
4. Chiara G., Isaac S., Harris M., Tak M. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov, 2013; 12: 931-947. | |
| |
5. Freshney R.I. Culture of animal cells: a manual of basic technique and specialized applications: Wiley-Backwell, 2010. 768 p. | |
| |
6. Han S., Hong C., Kim H., Lyu S. Anti-cancer effects of enteric-coated polymers containing mistletoe lectin in murine melanoma cells in vitro and in vivo. Mol. Cell Biochem, 2015; 15: 1-15. | |
| |
7. Korn E.L., Liu P.Y., Lee S.J. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol, 2008; 26: 527-34. | |
| |
8. Lehka L.V., Panchuk R.R., Berger W. et al. The role of reactive oxygen species in apoptosis of tumor cells induced by landomycin A. Ukrainian Biochemical Journal, 2015; 87(5): 72-82. | |
| |
9. Matsura T., Kai M., Fujii Y., Yamada H. Hydrogen Peroxide-induced Apoptosis Requires Caspase-3 Activation in HL-60 Cells. Free Rad. Res, 1998; 30: 73-83. | |
| |
10. Meyskens F.L., Jr. Farmer P., Fruehauf J.P. Redox regulation in human melanocytes and melanoma. Pigment Cell Res, 2001; 14: 148-54. | |
| |
11. Ronin V.S., Utevsky N.L. Textbook for classes on the methods of clinical laboratory investigations. 4th ed. Moscow: Medicine, 1989. 335 p. (In Russian) | |
| |
12. Tomayko M., Reynolds P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemotherapy and Pharmacology, 1989; 24(3): 148-154. | |
| |
13. Toyokuni S., Okamoto K., Yodoi J., Hiai H. Persistent oxidative stress in cancer. FEBS Letters, 1995; 358: 1-3. | |
| |
14. White N., Gillian K., Butler P., Burnstock G. An in vivo model of melanoma: treatment with ATP. Purinergic Signal, 2009; 5(3): 327-333. | |
| |
15. Wittgen H.G., Van Kempen L.C. Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res, 2007; 17: 400-9. | |
| |
16. Zhang X., Teodoro J., Nadeau Jay. Intratumoral gold-doxorubicin is effective in treating melanoma in mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015; 20: 1-11. | |
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Studia biologica
This work is licensed under a Creative Commons Attribution 4.0 International License.